SGI - PDFSEARCH.IO - Document Search Engine

SGI
Results: 840

#	Item
261	No[removed]SGI-110, a Novel Subcutaneous (SQ) Second Generation DNA Hypomethylating Agent Achieves Improved Pharmacodynamics (PD), Safety and Pharmacokinetics (PK) in comparison to IV Decitabine (DAC) in a non-human primat Add to Reading List Source URL: astx.com Language: English - Date: 2012-12-13 18:06:00 DNA DNA methylation Epigenetics
262	ABST # A190 In Vivo Activity of SGI-110, a Novel Hypomethylating Agent for Treatment in Hematology and Solid Malignancies Jason Scholl, David Vollmer, Jared Bearss, Carissa Jones, Virgil McCarthy, Paul Severson, Sanjeev Add to Reading List Source URL: astx.com Language: English - Date: 2012-12-13 18:06:00 DNA DNA methylation Epigenetics Myelodysplastic syndrome Hypomethylating agent Decitabine Biology Medicine Nucleosides Triazines
263	1442 Determinants of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study Woonbok Chung, PhD1, Pietro Taverna, PhD2, John F L Add to Reading List Source URL: astx.com Language: English P53 Programmed cell death Proteins Biology Cell biology Apoptosis
264	First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Jean Pierre Issa, MD Fels Institute, Temple Univ Add to Reading List Source URL: astx.com Language: English Triazines Acute leukemia Myeloid leukemia Acute myeloid leukemia Orphan drugs Azacitidine DNA methyltransferase Leukemia Epigenetics Oncology Medicine Nucleosides
265	First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous hypomethylating agent, in 102 patients with Intermediate or High Risk MDS or CMML On Behalf of the SGI-110 Investigative Team Guillerm Add to Reading List Source URL: astx.com Language: English Pharmacology Azacitidine lactams Chemistry Decitabine Hypomethylating agent DNA methyltransferase Nucleosides Triazines Medicine
266	Immunomodulatory activity of SGI-110, a 5-aza-2’-deoxycytidine-containing demethylating dinucleotide Sandra Coral , Luca Sigalotti , Giulia Parisi , Francesca Colizzi , Hugues JM Nicolay , Pietro Taverna and Michele Ma Add to Reading List Source URL: astx.com Language: English - Date: 2012-12-13 18:06:00 Tumor antigen Cell culture Melanoma Actin Cancer Biology Medicine HLA-A
267	Abstract No[removed]Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML) Simone Jueliger1, Add to Reading List Source URL: astx.com Language: English Epigenomics Methylation DNA methylation Hypomethylating agent Acute myeloid leukemia Cellular differentiation Genetics Biology Epigenetics
268	SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Fo Add to Reading List Source URL: astx.com Language: English - Date: 2012-12-13 18:06:00 Hypomethylating agent Health Toxicology Medicine Myelodysplastic syndrome Syndromes
269	Abst. No. 678 Evaluation of Oral Bioavailability and Intermittent Dosing Schedules for Pharmacodynamic Effects by SGI-110, a Novel Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA), in Male Cynomolgus Monke Add to Reading List Source URL: astx.com Language: English - Date: 2013-07-16 08:37:55 Piperazines Norfloxacin
270	Immunomodulatory activity of SGI-110, a 5-aza-2’-deoxycytidine-containing demethylating dinucleotide Sandra Coral1, Luca Sigalotti1, Ester Fonsatti2, Giulia Parisi1, Francesca Colizzi1, Hugues JM Nicolay1,2, Pietro Tav Add to Reading List Source URL: astx.com Language: English - Date: 2012-12-13 18:06:00 Tumor antigen Cell culture Melanoma Actin Mesothelioma Biology Medicine HLA-A

UPDATE